Reitamo S, Klockars M, Adinolfi M, Osserman E F
Ric Clin Lab. 1978 Oct-Dec;8(4):211-31.
Histochemical and in particular immunoperoxidase techniques have extended our knowledge about the cellular distribution of LZM. The enzyme has been detected in: 1. granulocytes, which synthesize LZM in bone marrow; 2. cells of the mononuclear phagocytic system, which synthesize LZM continuously; 3. various exocrine glands, whose LZM is probably in part synthesized locally and in part derived from blood; 4. cartilage, which probably synthesizes LZM and 5. the kidney, in which LZM is serum-derived. In pathological conditions, such as inflammation and neoplasia, most LZM-positive cells at the site of disease are either granulocytes or members of the mono-nuclear phagocytic system. A notable exception are the metaplastic Paneth cells that occur along the gastrointestinal tract in inflammation and neoplasia. LZM is an antibacterial agent, but evidence is accumulating which suggests that the enzyme might have other functions as well.
组织化学技术,尤其是免疫过氧化物酶技术,拓展了我们对溶菌酶(LZM)细胞分布的认识。已在以下细胞中检测到该酶:1. 粒细胞,其在骨髓中合成LZM;2. 单核吞噬系统的细胞,其持续合成LZM;3. 各种外分泌腺,其LZM可能部分在局部合成,部分来源于血液;4. 软骨,其可能合成LZM;5. 肾脏,其中的LZM来源于血清。在诸如炎症和肿瘤形成等病理状况下,疾病部位大多数LZM阳性细胞要么是粒细胞,要么是单核吞噬系统的成员。一个显著的例外是在炎症和肿瘤形成时沿胃肠道出现的化生潘氏细胞。LZM是一种抗菌剂,但越来越多的证据表明该酶可能还具有其他功能。